NASDAQ:ADXS - Advaxis, Inc.
$3.31
 $0.01
+0.30%
4:00PM EDT
2019-04-18
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ADXS     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 02   203. 85   241. 91  
42 stocks rank:  4. 36 K 1. 44 K 1. 05 K
# analyst opinions:  3. 00   14. 51   13. 97  
mean recommendation:  2. 70   2. 09   2. 01  

quick ratio:  2. 94   5. 27   1. 81  
current ratio:  3. 32   5. 62   2. 25  

target price low:  4. 30   84. 80   115. 21  
target price avg:  5. 87   111. 51   137. 51  
target price high:  4. 50   135. 81   157. 84  
1-yr high:  30. 30   114. 23   138. 78  
last close:  3. 31   87. 66   116. 69  
50-day avg:  5. 47   95. 54   123. 44  
200-day avg:  10. 46   94. 25   121. 11  
1-yr low:  2. 79   72. 78   98. 34  
volume:  206. 99 K 4. 11 M 8. 07 M
50-day avg volume:  723. 55 K 2. 76 M 5. 02 M
200-day avg volume:  361. 47 K 2. 92 M 4. 59 M

1-day return:  0. 30 % -0. 41 % 0. 07 %
this week return:  -6. 76 % -5. 74 % -4. 11 %
12-wk return:  -40. 36 % 1. 61 % -0. 05 %
52-wk return:  -86. 42 % 3. 12 % 8. 78 %

enterprise value (EV):  -17. 47 M 48. 94 B 114. 64 B
market cap:  26. 50 M 43. 07 B 104. 73 B
EBITDA:  -36. 44 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  0. 48   4. 22   12. 73  
enterprise/revenue (EV/R):  -0. 74   63. 17   12. 84  
total revenue:  23. 70 M 10. 62 B 38. 47 B
total debt:  0. 00   12. 24 B 16. 73 B
net income (common):  -33. 21 M 2. 20 B 4. 20 B

shares outstanding:  8. 01 M 571. 70 M 1. 24 B
shares:  3. 13 M 571. 81 M 1. 23 B
shares short:  246. 03 K 10. 17 M 13. 00 M
shares short prior month:  155. 38 K 9. 54 M 17. 33 M
short ratio:  1. 08   5. 41   3. 28  
short % of float:  5. 37 % 5. 45 % 2. 38 %
total cash/share:  7. 11   11. 14   9. 33  
total cash:  32. 71 M 6. 71 B 7. 15 B
free cash flow:  -29. 49 M 3. 58 B 2. 96 B
operating cash flow:  -61. 34 M 4. 15 B 4. 30 B

book value:  8. 15   12. 78   26. 92  
price/book:  0. 41   3. 06   -1. 74  
gross profits:  6. 06 M 8. 04 B 34. 86 B
operating margins:  -160. 23 % -725. 35 % -89. 04 %
EBITDA margins:  -153. 80 % 10. 94 % 22. 51 %
profit margins:  -140. 13 % 7. 81 % 10. 57 %
gross margins:  100. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  55. 26 % --- ---
1-yr mean volatility:  -0. 48 % 0. 03 % 0. 04 %

1-yr EPS:  -8. 71   2. 40   4. 10  
forward EPS:  -5. 92   3. 97   7. 13  
P/E:  -0. 38   13. 63   22. 72  
forward P/E:  -0. 56   -15. 95   13. 99  
PE/G:  -0. 00   -1. 65   -1. 32  
growth:  857. 60 % 127. 12 % 29. 61 %
earnings high:  0. 00   1. 00   1. 66  
earnings avg:  -1. 20   0. 77   1. 53  
earnings low:  -2. 40   0. 50   1. 39  
revenue high:  18. 66 M 2. 68 B 10. 78 B
revenue avg:  10. 33 M 2. 59 B 10. 57 B
revenue low:  2. 00 M 2. 49 B 10. 36 B
return on assets:  -37. 15 % -2. 75 % 4. 55 %
return on equity:  -86. 51 % -18. 45 % 5. 46 %
revenue growth:  857. 60 % 92. 86 % 18. 96 %
revenue/share:  6. 13   13. 29   55. 46  

beta (1yr vs S&P500):  1. 58   1. 25   0. 93  
sharpe (1yr):  -0. 92   0. 37   0. 70  

held % insiders:  3. 65 % 6. 39 % 3. 38 %
held % institutions:  28. 86 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : ADXS
.        + 0 =             0 :: INITIAL WEIGHT
.   + 41.329 =        41.329 :: spline projection addition
.    x 1.431 =        59.159 :: industry recommendation factor
.    x 1.243 =         73.52 :: symbol recommendation factor
.    x 0.996 =        73.247 :: return on assets factor
.    x 0.991 =        72.613 :: return on equity factor
.    x 3.711 =       269.436 :: revenue growth factor
.     x 2.59 =        697.73 :: current ratio factor
.    x 1.231 =       858.709 :: quick ratio factor
.    x 1.388 =      1191.697 :: short ratio factor
.    x 2.004 =      2388.235 :: price-to-book factor
.    x 1.055 =      2520.217 :: EBITDA multiple vs industry factor
.    x 5.618 =     14158.236 :: EBITDA multiple factor
.    x 2.171 =     30739.138 :: P/E weight
.    x 2.209 =     67901.499 :: PE/G factor
.    x 1.427 =      96899.77 :: beta factor
.    x 0.919 =     89038.402 :: sharpe factor
.    x 1.573 =    140063.981 :: target low factor
.    x 1.293 =     181094.78 :: target mean factor
.     x 1.06 =     191953.17 :: target high factor
.     x 1.31 =    251437.134 :: industry 2-weeks return factor
.    x 0.998 =    250945.138 :: overall "drift" factor
.    x 0.447 =    112264.915 :: largest single-day jump factor
.    x 0.072 =      8094.082 :: low price factor
.      x 1.0 =      8092.768 :: factor hist industry gain for week 16
.   cubeRoot =        20.077 :: reduced to standardize
.    - 31.35 =          0.02 :: add/subtract for performance
.                       0.02 :: FINAL WEIGHT for NASDAQ:ADXS


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org